Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-02-23 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos delivered in 2017
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2018, announcing the financial results for the full year 2017 ('Galapagos levert sterke resultaten over 2017'). It provides key financial highlights (revenue, operating loss, net loss, cash position) and management commentary. Crucially, the final section states: 'Op dit moment is Galapagos haar jaarrekening voor het jaar eindigend op 31 december 2017 aan het afronden. De commissaris heeft bevestigd dat de audit, die vrijwel klaar is... Galapagos gaat ervan uit dat het volledig geauditeerde jaarverslag over 2017 op of rond 23 maart 2018 gepubliceerd zal worden.' This indicates that the full, audited Annual Report (10-K equivalent) is not yet released, but the key results are being announced beforehand. This structure—announcing key financial figures and operational highlights before the final audited report—is characteristic of an Earnings Release (ER). While it contains detailed financial tables, its primary function here is the initial release of period results, not the comprehensive annual filing itself. FY 2017
2018-02-23 English
Galapagos delivered in 2017
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2018, presenting the financial results and key highlights for the full year 2017. It contains detailed financial tables (Revenues, Operating Loss, Net Result, Cash position) and management commentary on performance and outlook. This structure strongly indicates an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). Although it mentions the upcoming publication of the fully audited annual report (10-K) around March 23, 2018, this document itself is the preliminary announcement of those results, making ER the most appropriate classification. It is not the full 10-K, nor is it a transcript (CT) or a general regulatory filing (RNS) given the specific financial content. FY 2017
2018-02-23 English
FY2017_ENG.pdf
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2018, presenting the financial results and key highlights for the full year 2017. It contains detailed financial tables (revenues, operating loss, net result, cash position) and management commentary on performance and outlook. This structure strongly indicates an Earnings Release (ER). Although it mentions the upcoming 'Annual report 2017' publication date (March 23, 2018), the document itself is the preliminary announcement of the results, not the final audited report or a mere announcement of the report's publication. Therefore, ER is the most appropriate classification. FY 2017
2018-02-22 English
FY2017_NL.pdf
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2018, announcing the financial results for the full year 2017 ('Galapagos levert sterke resultaten over 2017'). It provides key financial highlights (revenue, operating loss, net loss, cash position) and management commentary. Crucially, the final section states: 'Op dit moment is Galapagos haar jaarrekening voor het jaar eindigend op 31 december 2017 aan het afronden. De commissaris heeft bevestigd dat de audit, die vrijwel klaar is... Galapagos gaat ervan uit dat het volledig geauditeerde jaarverslag over 2017 op of rond 23 maart 2018 gepubliceerd zal worden.' This indicates that the full, audited Annual Report (10-K equivalent) is not yet released, but the key results are being announced beforehand. This structure—announcing key financial figures and operational highlights before the final audited report—is characteristic of an Earnings Release (ER). While it contains detailed financial tables, its primary function here is the initial release of period results, not the comprehensive annual filing itself. FY 2017
2018-02-22 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to furnish reports or documents that are required to be made public under home country laws or exchange rules but are not annual reports (which would be Form 20-F or 40-F). The document includes a press release as Exhibit 99.1 and is relatively short (2655 characters). It does not contain financial statements or detailed financial data but rather serves as a regulatory filing to disclose information to the SEC. Therefore, this document fits the category of Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as an Annual Report, Earnings Release, or other specific report types.
2018-02-20 English
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
Earnings Release Classification · 95% confidence The document is a press release dated February 17, 2018, announcing the presentation of Phase 1 study results for a drug candidate (MOR106) at the American Academy of Dermatology (AAD) Meeting. It details clinical trial outcomes (efficacy, safety, dosing) and outlines future development plans (Phase 2 start). This content structure—announcing clinical data presentation and providing key results—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it focuses on the initial announcement of period-specific results (Phase 1 trial data presentation) rather than a comprehensive quarterly/annual financial report (10-K or IR), the most appropriate classification is Earnings Release (ER), as these often include operational highlights alongside financial snippets, or in this case, key clinical milestones which drive investor interest. It is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy statement (DEF 14A). It is an announcement of results, fitting the ER definition best among the options provided for non-financial performance announcements. Q1 2018
2018-02-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.